Summit Therapeutics PLC (NASDAQ:SMMT)‘s stock had its “buy” rating reissued by Canaccord Genuity in a report issued on Monday.

A number of other analysts have also recently commented on the company. Zacks Investment Research raised Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Tuesday, July 4th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Summit Therapeutics PLC in a research report on Monday, September 11th. Finally, ValuEngine cut Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $23.50.

Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded down 2.10% during mid-day trading on Monday, hitting $12.13. The stock had a trading volume of 45,729 shares. The firm’s market cap is $150.23 million. Summit Therapeutics PLC has a 52-week low of $7.95 and a 52-week high of $16.86. The stock’s 50-day moving average price is $12.92 and its 200-day moving average price is $12.92.

Summit Therapeutics PLC (NASDAQ:SMMT) last issued its quarterly earnings results on Thursday, August 31st. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.28). Summit Therapeutics PLC had a negative return on equity of 29,334.40% and a negative net margin of 12.44%. The company had revenue of $25.01 million during the quarter, compared to the consensus estimate of $31.37 million. On average, analysts anticipate that Summit Therapeutics PLC will post ($0.08) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Summit Therapeutics PLC (SMMT) Receives “Buy” Rating from Canaccord Genuity” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/16/summit-therapeutics-plc-smmt-receives-buy-rating-from-canaccord-genuity.html.

An institutional investor recently bought a new position in Summit Therapeutics PLC stock. Renaissance Technologies LLC bought a new stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 20,102 shares of the company’s stock, valued at approximately $267,000. Renaissance Technologies LLC owned about 0.16% of Summit Therapeutics PLC at the end of the most recent quarter. 21.77% of the stock is owned by institutional investors and hedge funds.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.